Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 15/20 | 0.81 |
| ▸ | CNR2 | P34972 | 10/20 | 0.81 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.64 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.56 |
| ▸ | MLNR | O43193 | 1/20 | 0.56 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.56 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL675967 | 0.91 | CNR1 (0.98) | CNR1CNR2CYP2C9GPR55CYP1A2 | |
| SCHEMBL5814976 | 0.90 | CNR1 (1.00) | CNR1CNR2CYP2C9GPR55CYP1A2 | |
| Hydrochloric Acid SCHEMBL3365683 | 0.90 | CNR1 (0.98) | CNR1CNR2CYP2C9GPR55CYP1A2 | |
| Hydrochloric Acid SCHEMBL3365107 | 0.89 | CNR1 (1.00) | CNR1CNR2CYP2C9GPR55CYP1A2 | |
| SCHEMBL17645251 | 0.82 | CNR1 (0.56) | CNR1CNR2CYP2C9GPR55KDM4E | |
| SCHEMBL674988 | 0.82 | CNR1 (0.81) | CNR1CNR2 | |
| Hydrochloric Acid SCHEMBL3368663 | 0.81 | CNR1 (0.81) | CNR1CNR2 | |
| SCHEMBL3815250 | 0.78 | CNR2 (0.91) | CNR1CNR2CYP2C9GPR55KDM4E | |
| SCHEMBL29835959 | 0.78 | CNR1 (1.00) | CNR1CNR2CYP2C9GPR55KDM4E | |
| SCHEMBL3365144 | 0.78 | CNR1 (0.77) | CNR1CNR2CYP2C9GPR55CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1542678-B1 | 1H-1,2,4-TRIAZOLE-3-CARBOXAMIDE DERIVATIVES AS CANNABINOID-CB sb 1 /sb RECEPTOR LIGANDS | SOLVAY PHARM BV (NL) | 2010-02-24 | — | — | EP | disclosed |
| US-7319110-B2 | 1H-1,2,4-triazole-3-carboxamide derivatives having cannabinoid-CB1 receptor agonistic, partial agonistic, inverse agonistic or antagonistic activity | SOLVAY PHARMACEUTICALS B.V. (NL) | 2008-01-15 | — | — | US | disclosed |
| WO-2006030285-A1 | NEW 1,2,4-TRIAZOLE-3-CARBOXAMIDE DERIVATIVES | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-03-23 | — | — | WO | disclosed |
| EP-1542678-A1 | 1H-1,2,4-TRIAZOLE-3-CARBOXAMIDE DERIVATIVES AS CANNABINOID-CB sb 1 /sb RECEPTOR LIGANDS | Solvay Pharmaceuticals B.V. (NL) | 2005-06-22 | — | — | EP | disclosed |
| US-20050124660-A1 | Compounds for treatment of diseases using enzyme inhibitors, cognition activators for nervous system disorders, psychological disorders or obesity in children | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-06-09 | — | — | US | disclosed |
| US-20040106614-A1 | 1H-1,2,4-triazole-3-carboxamide derivatives having cannabinoid-CB1 receptor agonistic, partial agonistic, inverse agonistic or antagonistic activity | SOLVAY PHARMACEUTICALS B.V. (NL) | 2004-06-03 | — | — | US | disclosed |
| WO-2004026301-A1 | 1H-1,2,4-TRIAZOLE-3-CARBOXAMIDE DERIVATIVES AS CANNABINOID-CB1 RECEPTOR LIGANDS | SOLVAY PHARMACEUTICALS B.V. (NL) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106614-A1 | 1H-1,2,4-triazole-3-carboxamide derivatives having cannabinoid-CB1 receptor agonistic, partial agonistic, inverse agonistic or antagonistic activity | CNR1, CNR2, GPR3 | CNR1 1/4885CNR2 2/4885CYP2C9 1502/4885 |
| US-20050124660-A1 | Compounds for treatment of diseases using enzyme inhibitors, cognition activators for nervous system disorders, psychological disorders or obesity in children | PNLIP, DLAT, LPCAT3 | CNR1 46/4885CNR2 28/4885CYP2C9 2475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.